Cyprotex, a specialist ADME-Tox CRO, is planning the expansion of its U.K. facility into BioHub, a new bioscience center at AstraZeneca’s Alderley Park research campus near Manchester, England.

BioHub will provide Cyprotex with additional capacity for laboratories and office space. The laboratories include fully-equipped cell culture facilities and radiochemical handling capabilities.

This expansion follows highly encouraging growth figures for the business in the first six months of the year, with a revenue increase of 22.3% in the first quarter compared to the year-ago period and a record half-year operating profit of $509,000. Performance remains strong across all geographical markets and main service operations of high throughput ADME, customized ADME and toxicology.